# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Kuros Biosciences AG ("Kuros" or the "Company"), a leader in next generation bone graft technologies, notes th...
Checkmate Pharmaceuticals (NASDAQ:CMPI) reported quarterly losses of $(0.73) per share. This is a 12.31 percent decrease over l...
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to...
Upgrades
BTIG analyst Kaveri Pohlman downgrades Checkmate Pharmaceuticals (NASDAQ:CMPI) from Buy to Neutral.
Gainers
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.